Diabetic Macular Edema
Conditions
Keywords
Diabetic Macular Edema, Ciliary Body, Ultrasound Biomicroscopy, Vitrectomy
Brief summary
The purpose of this study is to determine whether ciliary body thickness increased in the presence of diabetic macular edema and whether it changed after pars plana vitrectomy.
Detailed description
A diabetic macular edema group consisted of diabetic patients who underwent PPV for diffuse diabetic macular edema. A epiretinal membrane group, a surgical control group, consisted of non-diabetic patients with epiretinal membrane who underwent pars plana vitrectomy. A healthy control was also included for the comparison of preoperative ciliary body thickness. Ciliary body thickness was measured using ultrasound biomicroscopy, and central macular thickness was determined using optical coherence tomography. The visual outcome, ciliary body thickness, and central macular thickness were compared between groups before and 1, 2, and 4 months after pars plana vitrectomy and the correlations between the central macular thickness and ciliary body thickness and best corrected visual acuity were determined.
Interventions
PROCEDUREPars Plana Vitrectomy
25-gauge three-port pars plana vitrectomy
Sponsors
Ministry of Health & Welfare, Korea
Seoul National University Hospital
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
for diabetic macular edema group: * Diabetic macular edema with preoperative central macular thickness \> 300 μm on optical coherence tomography * Macular edema that was not associated with an epiretinal membrane or traction membrane * No combined traction retinal detachment or vitreous hemorrhage * No signs of ocular inflammatory disease on preoperative examination * Phakic eye * An axial length between 22.0 mm and 25.0 mm
Exclusion criteria
for diabetic macular edema group: * Patients with uveitis, inflammatory connective tissue disorders or a history of previous ocular surgery * Long-term application of topical medication, a history of intravitreal steroid or anti-VEGF injection within 3 months before vitrectomy Inclusion Criteria for epiretinal membrane group: * Non-diabetic patients with an epiretinal membrane who were scheduled for vitrectomy * No ocular or systemic disease other than epiretinal membrane Inclusion Criteria for healthy group: * No diabetes * No ocular disease other than cataract
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| ciliary body thickness | up to four months after surgery | ciliary body thickness was determined using ultrasound biomicroscopy |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| central macular thickness | up to four months after surgery | central macular thickness was determined using optical coherence tomography |
Countries
South Korea
Outcome results
None listed